With the advent of John Fung (USA) being elected as TTS President-Elect (2022-2024), the Vice President position (2022-2026) will be vacated at the end of the TTS 2022 Congress. This by-election is being held to fill this new vacancy.
Minnie Sarwal is a pediatric and adult transplant nephrologist who has worked in the field of transplantation since 1997. She has trained and worked in 3 continents (Asia, Europe and North America), and is passionate about improving outcomes after organ transplantation for both children and adult transplant recipients, globally. She has dedicated her career to advancing mechanisms and management of transplant rejection by innovations in immunosuppression design and diagnostic biomarkers, and directs an NIH-funded Precision Transplant Lab and has authored over 300 peer reviewed publications. She has been an elected IPTA Councilor (2006), IPTA Outreach Committee Chair (2010-2015), TTS KOL (2008-2012), elected TTS Councilor (2014-2018), TTS Junior Treasurer (2018-2020) and TTS Senior Treasurer (2020-2022). She founded the TTS-Transplantomics meeting (2010-15) and advises the FDA Commissioner on the FDA Science Board (2017- 2022). She is currently a Professor in Residence, Department of Surgery, the Medical Director of the Kidney-Pancreas Transplant Program and Co-Director of the T32 Training Grant in Transplant Surgery, at the University of California San Francisco (UCSF). She has previously been Professor, Pediatrics and Surgery, and Medical Director of the Pediatric Kidney Transplant Program at Stanford University where she developed the first complete steroid avoidance program for renal transplantation in infants and children. A prolific speaker and educator, Minnie holds the TTS-Roche Award for Outstanding Achievement in Transplantation Science (2010), National Kidney Foundation- Cuneo Richardson Award for Excellence in Research (2012), is a Capstone Mentor for the Berkeley-Haas Masters in Translational Medicine (MTM; 2015-2022) and is Chief Editor, Frontiers in Nephrology (Nature). Her vision for TTS is to improve outreach, alliances and advances in technology and diagnostics globally and to developing countries to improve outcomes and equity in transplantation.
Stefan G. Tullius, MD, PhD, FACS, is the Joseph E. Murray, MD Distinguished Chair in Transplant Surgery, Professor of Surgery, Harvard Medical School. He has roots in both Europe and the USA, and collaborations around the world. After training in Berlin, he was appointed Chief of Transplant Surgery and Director of the Transplant Surgery Research Lab at Brigham & Women’s Hospital, Boston, in 2005. Dr. Tullius has served as Councilor and Treasurer for TTS and has been on the Boards of ESOT and UNOS. He is currently a Board member of the National Kidney Registry and Vice President of the Int’l Society of Uterus Transplantation, now a section of TTS. He is an Executive Editor, Transplantation, a position he has held since 2014. He is also an Associate Editor of Transplant International (since 2004), the Korean Journal of Transplantation, and has been an Associate Editor for AJT. In addition to being an active transplant surgeon, Dr. Tullius runs a prolific NIHfunded laboratory. His international collaborations include institutions in China, India, Argentina, Japan and Germany. Dr. Tullius is proud of his many clinical and research mentees who have moved on with their own successful clinical and research careers. His own work has been recognized with several awards including the Clinical Science Investigator Award of the AST, Excellence in Transplantation Award by the National Kidney Foundation, and the Outstanding Ach ievement Award by TTS. Dr. Tullius looks forward to serving TTS advancing the society’s international clinical, scientific, and ethical mission.
To participate in the election you must be a Full Member of TTS with paid 2022 membership dues. We look forward to your participation in the election.
For any issues with the login, please contact our Membership Services Coordinator (firstname.lastname@example.org).
The Importance of Prioritizing Pre and Posttransplant Immunizations in an Era of Vaccine Refusal and Epidemic Outbreaks #TBTVaccine-preventable infections are occurring at epidemic rates both nationally and internationally. At the same time, rates of vaccine hesitancy and refusal are increasing across the country leading to decreased herd immunity. For immunosuppressed transplant recipients, this situation poses great risk. Currently, 1 in 6 pediatric solid organ transplant recipients is hospitalized with a vaccine-preventable infection in the first 5 years posttransplant. For many recipients, these infections result in significant morbidity, mortality, and increased hospitalization costs. Surprisingly, despite this risk many transplant recipients are not up-to-date on age appropriate immunizations at the time of transplant and thereafter.
Katherine Stultz, President and CEO of Ocelot Bio, will lead a session on “Achieving Gender Equality in the Life Science World: from Compensation to Career Opportunities in Industry and Academia”, on Thursday June 23rd at 11:30-12:45 local time (Pacific Time). This will be followed by discussion with the participants and leads of WICI and WIT.
The FOCIS meeting will be held from June 21-24, 2022.
WIT members who are registered for and attending FOCIS will receive complimentary registration for the Networking session. Please follow this link to register: https://www.surveymonkey.com/r/5DTYN76